CA
TCRX icon

Cliff Asness’s TScan Therapeutics TCRX Stock Holding History

Cliff Asness’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,438
Closed -$32.5K – 3590
2025
Q2 		$32.5K Buy
+22,438
New +$32.4K ﹤0.01% 3262
2024
Q4 		– Sell
-12,913
Closed -$64.3K – 2951
2024
Q3 		$64.3K Buy
+12,913
New +$77.9K ﹤0.01% 2693

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Cliff Asness's TCRX Position: Q3 2025 in Review

Cliff Asness sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 22,438 shares — an estimated $32.5K sold.

Cliff Asness first reported a position in TCRX in Q3 2024 and held it in 2 quarters. The position peaked at $64.3K in Q3 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Cliff Asness reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cliff Asness sold 22,438 TScan Therapeutics shares in Q3 2025, an estimated $32.5K.
  • Cliff Asness first reported a position in TScan Therapeutics in Q3 2024 and held it in 2 quarters.
  • Cliff Asness's TScan Therapeutics position peaked at $64.3K in Q3 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.